Shimizu, Toshio
Nakajima, Takako Eguchi
Yamamoto, Noboru
Yonemori, Kan
Koyama, Takafumi
Kondo, Shunsuke
Sunakawa, Yu
Izawa, Naoki
Horie, Yoshiki
Xiang, Silong
Xu, Siying
Qin, Lan
Gong, John
Liu, David
Article History
Received: 25 May 2022
Accepted: 15 July 2022
First Online: 6 August 2022
Declarations
:
: Dr. Toshio Shimizu (TS) received research grants from 3D Medicine related to the submitted work; and research grants from Novartis, Eli Lilly, Loxo Oncology, Daiichi-Sankyo, AbbVie, Bristol-Myers Squibb, Eisai, AstraZeneca, Pfizer, Takeda Oncology, Incyte, Chordia Therapeutics, Symbio Pharmaceuticals, PharmaMar, Astellas; and advisory role fees from AbbVie, Daiichi-Sankyo, Takeda Oncology, Chordia Therapeutics; and personal fees (speakers) from Eli Lilly, Chugai Pharmaceutical Co., Taiho, Boehringer Ingelheim, MSD outside the submitted work. Dr. Noboru Yamamoto (NY) received research grants from Astellas, AstraZeneca, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi; and advisory role fees from Eisai, Takeda, Otsuka, Boehringer Ingelheim, Cimic, Chugai; and personal fees (speakers) from AstraZeneca, Eli Lilly, ONO, Chugai, Sysmex, Daiichi-Sankyo, Eisai outside the submitted work. Dr. Kan Yonemori (KY) received research grants from MSD, Daiichi-Sankyo, Astrazeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boeringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, Haihe; and advisory role fees from Novartis, Eisai, AstraZeneca, Chugai, Takeda, Genmab, OncXerna; and personal fees from Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma outside the submitted work. Dr. Shunsuke Kondo (SK) received research grants from Takeda, AstraZeneca, Abbie, Eli Lilly, MSD, Boehringer Ingelheim, Chugai, Eisai, Incyte, Pfizer; and personal fees from Chugai, Incyte, Takeda, Chugai, Termo, and Eisai outside the submitted work. Dr. Takafumi Koyama (TK) received research grants from Novartis, Daiichi-Sankyo, Eli Lilly, PACT Pharma; and personal fees from Chugai and Sysmex outside the submitted work. Dr. NAKAJIMA reports grants and personal fees from Sumitomo Dainippon Pharma Co., personal fees from Boehringer Ingelheim , personal fees from Bristol-Myers Squibb, grants and personal fees from Ono Pharmaceutical Co., grants and personal fees from Taiho Pharmaceutical Co., personal fees from Amgen, grants and personal fees from Takeda Pharmaceutical Co., grants and personal fees from Chugai Pharmaceutical Co., grants and personal fees from Sanofi K.K., personal fees from Novartis Japan, grants and personal fees from Nippon Kayaku Co., grants and personal fees from MSD K.K., grants and personal fees from Eli Lilly Japan K.K., personal fees from Bayer Yakuhin, personal fees from Pfizer Japan Inc., personal fees from Daiichi Sankyo Co., personal fees from Yakult Honsha Co., personal fees from Nipro Co, personal fees from Merck Serono Co., grants from PAREXEL, grants from JCRO, grants from SHIONOGI & CO., LTD., personal fees from AstraZeneca, personal fees from IQVIA, personal fees from GlaxoSmithKline, outside the submitted work; Yu Sunakawa; Research funding and honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, Takeda, Eli Lilly Japan, and Sanofi Honoraria from Bristol-Myers Squibb Japan, Merck Biopharma, Ono Pharmaceutical, Bayer Yakuhin, MSD, Daiichi Sankyo, Sysmex and Guardant Health Naoki Izawa: Honoraria from Taiho Pharmaceutical, Takeda, Eli Lilly Japan, and Bristol-Myers Squibb Japan Yoshiki Horie: No. COI Silong Xiang, Siying Xu, Lan Qin, John Gong, and David Liu are employees of and own stock in 3D Medicines Co., Ltd. JG and DL have leadership roles at 3D Medicines Co., Ltd.